|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effect of electrically stimulating acupoint, Zusanli(ST 36), on patient’s recovery after laparoscopic colorectal cancer resection: a randomized controlled trial显示文摘OBJECTIVE:To investigate the effect of transcutaneous electrical acupoint stimulation (TEAS) on enhanced recovery after surgery (ERAS) in laparoscopic colorectal cancer resection and its clinical significance.METHODS:Sixty-four patients undergoing laparoscopic colorectal resection were randomly divided into two groups,the control group (group A) and the TEAS group (group B).Patients in the TEAS group received electroacupuncture stimulation of bilateral Zusanli (ST 36) at 30 min before anesthesia to the end of surgery.The patients in the control group were not given the stimulation.Perioperative anesthesia management of the two groups were performed according to the ERAS guidelines,and postoperative patient-controlled intravenous analgesia (PCIA) was used.The amount of remifentanil used in the two groups was observed and recorded,and the visual analogue scale (VAS) of the 4,12,24 and 48 h after surgery in the two groups was recorded.Moreover,postoperative anal exhaust time,postoperative feeding time,postoperative first ambulation time and postoperative hospital stay length were compared between the two groups.RESULTS:Compared with group A,the VAS score of group B decreased significantly at 48 h after operation (P < 0.05).The postoperative anal exhaust time in group B was significantly shorter than that of group A (P < 0.05).There was no significant difference between the two groups with regards to remifentanil consumption,postoperative feeding time,postoperative first ambulation time and postoperative hospital stay (all P > 0.05).CONCLUSION:TEAS can promote the recovery of postoperative gastrointestinal function and reduce the pain intensity 48 h after surgery,thus satisfying the need of early postoperative analgesia. | Huang Wei Yu Tingyu Long Wenfei Xiao Jianbin Zhao Gaofeng | 2019 | Journal of Traditional Chinese Medicine2019，39，3： | 14 |
| 2 | Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection显示文摘COVID-19 caused by SARS-CoV-2 infection has caused substantial morbidity and mortality worldwide and paralyzed the international economy.Understanding the magnitude and duration of the antibody response to SARS-CoV-2 is important to achieve a balance between curbing the pandemic and minimizing adverse effects on society.1 Although the antibody response to SARS-CoV-2 within 9 months has been extensively studied,2,3,4,5,6 little is known about the magnitude and kinetics of antibody responses for over 9 months.Moreover,with limited observations over 9 months(n<100),2,7,8 several studies have produced inconsistent conclusions about antibody dynamics,suggesting different rates of antiviral antibody positivity at the last follow-up.2,7,8 These studies have been limited by a lack of measurement of neutralizing antibodies(NAbs),7 of inclusion of mild or asymptomatic cases,2,8 and of further exploration of potential predisposing factors for antibody dynamics.2,7 Considering the individual heterogeneity(such as disease severity)8 and time-dependent nature1 of the immune response,in-depth characterization of SARS-CoV-2 antibody kinetics across disease severity groups over a long period is urgently needed.Therefore,we repeatedly tested IgM,IgG,viral spike protein receptor-binding dom(anti-RBD)IgG,and NAb titers in COVID-19 patients during a follow-up period of up to 10 months and explored potential predisposing factors of antibody titers during follow-up. | Hao Wang Yu Yuan Mingzhong Xiao Li Chen Youyun Zhao Haiwei Zhang Pinpin Long Yana Zhou Xi Xu Yanshou Lei Bihao Wu Tingyue Diao Hao Cai Li Liu Zuoyu Shao Jingzhi Wang Yansen Bai Kai Wang Miao Peng Linlin Liu Shi Han Fanghua Mei Kun Cai Yake Lei An Pan Chaolong Wang Rui Gong Xiaodong Li Tangchun Wu | 2021 | Cellular & Molecular Immunology2021，18，7： | 1 |
| 3 | Deep Segmentation Feature-Based Radiomics Improves Recurrence Prediction of Hepatocellular Carcinoma显示文摘Objective and Impact Statement.This study developed and validated a deep semantic segmentation feature-based radiomics(DSFR)model based on preoperative contrast-enhanced computed tomography(CECT)combined with clinical information to predict early recurrence(ER)of single hepatocellular carcinoma(HCC)after curative resection.ER prediction is of great significance to the therapeutic decision-making and surveillance strategy of HCC.Introduction.ER prediction is important for HCC.However,it cannot currently be adequately determined.Methods.Totally,208 patients with single HCC after curative resection were retrospectively recruited into a model-development cohort(n=180)and an independent validation cohort(n=28).DSFR models based on different CT phases were developed.The optimal DSFR model was incorporated with clinical information to establish a DSFR-C model.An integrated nomogram based on the Cox regression was established.The DSFR signature was used to stratify high-and low-risk ER groups.Results.A portal phase-based DSFR model was selected as the optimal model(area under receiver operating characteristic curve(AUC):development cohort,0.740;validation cohort,0.717).The DSFR-C model achieved AUCs of 0.782 and 0.744 in the development and validation cohorts,respectively.In the development and validation cohorts,the integrated nomogram achieved C-index of 0.748 and 0.741 and time-dependent AUCs of 0.823 and 0.822,respectively,for recurrence-free survival(RFS)prediction.The RFS difference between the risk groups was statistically significant(P<0.0001 and P=0.045 in the development and validation cohorts,respectively).Conclusion.CECT-based DSFR can predict ER in single HCC after curative resection,and its combination with clinical information further improved the performance for ER prediction. | Jifei Wang Dasheng Wu Meili Sun Zhenpeng Peng Yingyu Lin Hongxin Lin Jiazhao Chen Tingyu Long Zi-Ping Li Chuanmiao Xie Bingsheng Huang Shi-Ting Feng | 2022 | Biomedical Engineering Frontiers2022，3，1： | 0 |
| 4 | Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents显示文摘Emerging SARS-CoV-2 variants have made COVID-19 convalescents susceptible to re-infection and have raised concern about the efficacy of inactivated vaccination in neutralization against emerging variants and antigen-specific B cell response.To this end,a study on a long-term cohort of 208 participants who have recovered from COVID-19 was conducted,and the participants were followed up at 3.3(Visit 1),9.2(Visit 2),and 18.5(Visit 3)months after SARS-CoV-2 infection.They were classified into three groups(no-vaccination(n=54),one-dose(n=62),and two-dose(n=92)groups)on the basis of the administration of inactivated vaccination.The neutralizing antibody(NAb)titers against the wild-type virus continued to decrease in the no-vaccination group,but they rose significantly in the one-dose and two-dose groups,with the highest NAb titers being observed in the two-dose group at Visit 3.The NAb titers against the Delta variant for the no-vaccination,one-dose,and two-dose groups decreased by 3.3,1.9,and 2.3 folds relative to the wild-type virus,respectively,and those against the Omicron variant decreased by 7.0,4.0,and 3.8 folds,respectively.Similarly,the responses of SARS-CoV-2 RBD-specific B cells and memory B cells were boosted by the second vaccine dose.Results showed that the convalescents benefited from the administration of the inactivated vaccine(one or two doses),which enhanced neutralization against highly mutated SARS-CoV-2 variants and memory B cell responses.Two doses of inactivated vaccine among COVID-19 convalescents are therefore recommended for the prevention of the COVID-19 pandemic,and vaccination guidelines and policies need to be updated. | Hao Wang Yu Yuan Bihao Wu Mingzhong Xiao Zhen Wang Tingyue Diao Rui Zeng Li Chen Yanshou Lei Pinpin Long Yi Guo Xuefeng Lai Yuying Wen Wenhui Li Hao Cai Lulu Song Wei Ni Youyun Zhao Kani Ouyang Jingzhi Wang Qi Wang Li Liu Chaolong Wang An Pan Xiaodong Li Rui Gong Tangchun Wu | 2023 | Frontiers of Medicine2023，17，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员